said Dr. Budson. Normal beta amyloid CSF levels, elevated CSF p-tau/tau ratio, negative amyloid imaging,
as well as cortical atrophy beyond that expected for age
could also be signs of CTE. Potential experimental biomarkers include positive tau imaging and cortical thin-ning based on MRI.
Once physicians have made a diagnosis of prob-
able or possible CTE, there are several treatments
that may benefit patients, although no medications
are approved for the treatment of CTE. Cholinester-
ase inhibitors may help to treat memory impairment,
said Dr. Budson. For patients with depression and
anxiety, selective serotonin reuptake inhibitors may
be helpful. For patients with violent or explosive be-
havior, atypical neuroleptics may be efficacious. Me-
mantine may benefit patients with moderate or severe
dementia. Finally, to manage agitation, a combina-
tion of dextromethorphan and quinidine may be a
treatment option. NR
Montenigro PH, Baugh CM, Daneshvar DH, et al. Clinical subtypes of chronic
traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther.
2014; 6( 5):68.
Jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC.
This activity is supported by an independent educational grant from ACADIA Pharmaceuticals Inc.
Earn Up to 1.0 AMA PRA Category 1 Credit™
Parkinson’s Disease Psychosis
New Strategies to Optimize Care for Patients With
Did you know that more
than half of your patients
with Parkinson’s disease
may experience psychosis
during the course
of their illness?
Find out what’s new in
and management of
Parkinson’s disease psychosis.
Look for this supplement
online in the Education Section of
© 2016 MedEdicus LLC